Pyronaridine-artesunate versus mefloquine plus artesunate for malaria.

BACKGROUND Pyronaridine-artesunate is an artemisinin-based combination therapy under evaluation for the treatment of Plasmodium falciparum and P. vivax malaria. METHODS We conducted a phase 3, open-label, multicenter, noninferiority trial that included 1271 patients between 3 and 60 years of age from Asia (81.3%) or Africa (18.7%) with microscopically confirmed, uncomplicated P. falciparum malaria. Patients underwent randomization for treatment with a fixed-dose combination of 180 mg of pyronaridine and 60 mg of artesunate or with 250 mg of mefloquine plus 100 mg of artesunate. Doses were calculated according to body weight and administered once daily for 3 days. RESULTS Pyronaridine-artesunate was noninferior to mefloquine plus artesunate for the primary outcome: adequate clinical and parasitologic response in the per-protocol population on day 28, corrected for reinfection with the use of polymerase-chain-reaction (PCR) genotyping. For this outcome, efficacy in the group receiving pyronaridine-artesunate was 99.2% (743 of 749 patients; 95% confidence interval [CI], 98.3 to 99.7) and that in the group receiving mefloquine plus artesunate was 97.8% (360 of 368 patients; 95% CI, 95.8 to 99.1), with a treatment difference of 1.4 percentage points (95% CI, 0.0 to 3.5; P=0.05). In the intention-to-treat population, efficacy on day 42 in the group receiving pyronaridine-artesunate was 83.1% (705 of 848 patients; 95% CI, 80.4 to 85.6) and that in the group receiving mefloquine plus artesunate was 83.9% (355 of 423 patients; 95% CI, 80.1 to 87.3). In Cambodia, where there were 211 study patients, the median parasite clearance time was prolonged for both treatments: 64 hours versus 16.0 to 38.9 hours in other countries (P<0.001, on the basis of Kaplan-Meier estimates). Kaplan-Meier estimates of the recrudescence rate in the intention-to-treat population in Cambodia until day 42 were higher with pyronaridine-artesunate than with mefloquine plus artesunate (10.2% [95% CI, 5.4 to 18.6] vs. 0%; P=0.04 as calculated with the log-rank test), but similar for the other countries combined (4.7% [95% CI, 3.3 to 6.7] and 2.8% [95% CI, 1.5 to 5.3], respectively; P=0.24). Elevated levels of aminotransferases were observed in those receiving pyronaridine-artesunate. Two patients receiving mefloquine plus artesunate had seizures. CONCLUSIONS Fixed-dose pyronaridine-artesunate was efficacious in the treatment of uncomplicated P. falciparum malaria. In Cambodia, extended parasite clearance times were suggestive of in vivo resistance to artemisinin. (Funded by Shin Poong Pharmaceutical Company and the Medicines for Malaria Venture; ClinicalTrials.gov number, NCT00403260.).

[1]  R. Price,et al.  Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Tjitra,et al.  Pyronaridine-Artesunate versus Chloroquine in Patients with Acute Plasmodium vivax Malaria: A Randomized, Double-Blind, Non-Inferiority Trial , 2011, PloS one.

[3]  R. Price,et al.  Artemisinin combination therapy for vivax malaria. , 2010, The Lancet. Infectious diseases.

[4]  O. Gaye,et al.  Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial , 2010, The Lancet.

[5]  T. Fazili,et al.  Severe falciparum malaria: a case report. , 2010, The Journal of the Oklahoma State Medical Association.

[6]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[7]  P. Guérin,et al.  Global resistance surveillance: ensuring antimalarial efficacy in the future , 2009, Current opinion in infectious diseases.

[8]  Remington Nevin.  Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis , 2009, Malaria Journal.

[9]  K. Silamut,et al.  Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.

[10]  Paul Garner,et al.  Artemisinin-based combination therapy for treating uncomplicated malaria. , 2009, The Cochrane database of systematic reviews.

[11]  K. Thimasarn,et al.  Malaria trends and challenges in the Greater Mekong Subregion. , 2009, The Southeast Asian journal of tropical medicine and public health.

[12]  Richard J Maude,et al.  The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia , 2009, Malaria Journal.

[13]  M. Fukuda,et al.  Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.

[14]  B. Cissé,et al.  Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. , 2008, The Journal of infectious diseases.

[15]  S. Meshnick,et al.  Declining Artesunate-Mefloquine Efficacy against Falciparum Malaria on the Cambodia–Thailand Border , 2008, Emerging infectious diseases.

[16]  K. Stȩpniewska,et al.  Pharmacokinetic Determinants of the Window of Selection for Antimalarial Drug Resistance , 2008, Antimicrobial Agents and Chemotherapy.

[17]  Organización Mundial de la Salud.  Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations , 2008 .

[18]  Eric Legrand,et al.  Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6 , 2005, The Lancet.

[19]  S. Satpathy,et al.  Severe falciparum malaria , 2004, Indian journal of pediatrics.

[20]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .

[21]  I. Felger,et al.  Genotyping of Plasmodium falciparum , 2002 .

[22]  I. Felger,et al.  Genotyping of Plasmodium falciparum. PCR-RFLP analysis. , 2002, Methods in molecular medicine.

[23]  Leon Aarons,et al.  Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance , 2000, Antimicrobial Agents and Chemotherapy.

[24]  R. Price,et al.  Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. , 1999, The American journal of tropical medicine and hygiene.

[25]  D. Kyle,et al.  In vitro sensitivity of Plasmodium falciparum to artesunate in Thailand. , 1999, Bulletin of the World Health Organization.

[26]  P. Ringwald,et al.  Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  P. Olliaro,et al.  Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. , 1998, Medecine tropicale : revue du Corps de sante colonial.

[28]  P. Ringwald,et al.  Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa , 1996, The Lancet.

[29]  N. White,et al.  Antimalarial pharmacokinetics and treatment regimens. , 1992, British journal of clinical pharmacology.

[30]  L. Kerr,et al.  Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. , 1992, The Journal of tropical medicine and hygiene.